Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia. Bhreathnach U, Doherty D, Murphy K, Flynn CM, et al. Leuk Res 2022;116:106823.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Bhreathnach U, Doherty D, Murphy K, Flynn CM, et al. Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia. Leuk Res 2022;116:106823.
PMID: 35303627